Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
595 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.
96% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 45
27% more call options, than puts
Call options by funds: $551M | Put options by funds: $435M
15% more capital invested
Capital invested by funds: $26B → $30B (+$4.01B)
6% more funds holding
Funds holding: 559 → 595 (+36)
2% more repeat investments, than reductions
Existing positions increased: 218 | Existing positions reduced: 214
0% more funds holding in top 10
Funds holding in top 10: 19 → 19 (0)
Top Buyers
| 1 |
Jennison Associates
New York
|
+$636M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$118M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$83.6M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$69.1M |
| 5 |
Alkeon Capital Management
New York
|
+$67.9M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$328M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$213M |
| 3 |
Goldman Sachs
New York
|
-$183M |
| 4 |
State Street
Boston,
Massachusetts
|
-$82.3M |
| 5 |
BlackRock
New York
|
-$77.3M |
ALXN Hedge Fund Activity: Q3 2017 in Review
595 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new ALXN positions and 45 closed out — a net gain of 43 holders — while 218 added to existing stakes and 214 trimmed.
The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.
- 595 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
- Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
- 88 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +43 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
- The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.
Based on aggregated 13F filings for Q3 2017.